December 27, 2014 2:29 PM ET

Biotechnology

Company Overview of Maxygen, Inc.

Company Overview

Maxygen, Inc., a biopharmaceutical company, focuses on the discovery and development of protein pharmaceuticals for the treatment of disease and serious medical conditions in the United States. It focuses on developing MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.

411 Borel Avenue

Suite 616

San Mateo, CA 94402

United States

Founded in 1996

3 Employees

Phone:

650-241-2292

Fax:

650-257-5892

Key Executives for Maxygen, Inc.

Executive Chairman of The Board
Age: 67
Chief Patent Counsel and Vice President of Intellectual Property
Senior Vice President of Research and Development
Age: 57
Senior Vice President of Danish Operations and Senior Vice President of Global Project Management
General Counsel and Corporate Secretary
Age: 45
Compensation as of Fiscal Year 2014.

Maxygen, Inc. Key Developments

Maxygen, Inc. Announces Final Liquidating Distribution, Payable on About June 30, 2014

Maxygen, Inc. announced that, in accordance with the plan of dissolution approved by its shareholders on August 12, 2013, its Board of Directors has approved a second and final liquidating distribution in the amount of $0.093 per share of common stock. The final liquidating distribution will have a record date of August 29, 2013, which is the date on which the company filed its certificate of dissolution with the Secretary of State of Delaware and closed its stock transfer books. The company will make no further distributions beyond the final liquidating distribution. There is no requirement for stockholders to surrender shares in connection with the final liquidating distribution. Maxygen expects to pay this final liquidating distribution in cash on or about June 30, 2014.

Maxygen Files Form 15

Maxygen, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.0001 per share.

Maxygen Announces Filing Of Certificate of Dissolution; Delisting From NASDAQ

Maxygen, Inc. announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which will become effective at 5:00 p.m. Eastern Time on August 29, 2013. The filing of the certificate was made pursuant to a plan of dissolution approved by shareholders at the company’s annual meeting held on August 12, 2013. Maxygen notified The NASDAQ Stock Market (NASDAQ) of the filing and NASDAQ has advised Maxygen that trading of the company’s common stock will be suspended after the regular market officially closes at 4:00 p.m. Eastern Time on August 29, 2013. NASDAQ also has advised Maxygen that it will file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (SEC) to delist the common stock from NASDAQ. Maxygen also intends to seek relief from the SEC to suspend certain of its reporting obligations under the Securities and Exchange Act of 1934, as amended. In connection with the effectiveness of the certificate of dissolution, Maxygen will also close its stock transfer books and discontinue recording transfers of its common stock, effective as of 5:00 p.m. Eastern Time on August 29, 2013. As a result, the common stock, and stock certificates evidencing the shares of common stock, will no longer be assignable or transferable on the company’s books, other than transfers by will, intestate succession or operation of law.

Similar Private Companies By Industry

Company Name Region
TheraTarget, Inc. United States
Sierra Diagnostics Inc United States
BioCarta LLC United States
BiosPacific, Inc. United States
Arbor Vita Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Maxygen, Inc., please visit www.maxygen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.